West Pharmaceutical Services (NYSE:WST) Hits New 12-Month High After Earnings Beat

West Pharmaceutical Services, Inc. (NYSE:WST)’s stock price hit a new 52-week high on Thursday following a stronger than expected earnings report. The stock traded as high as $386.00 and last traded at $362.5410, with a volume of 169878 shares changing hands. The stock had previously closed at $358.41.

The medical instruments supplier reported $2.37 earnings per share for the quarter, beating analysts’ consensus estimates of $2.08 by $0.29. The firm had revenue of $872.30 million for the quarter, compared to analyst estimates of $839.98 million. West Pharmaceutical Services had a net margin of 16.85% and a return on equity of 19.03%. The business’s quarterly revenue was up 13.8% compared to the same quarter last year. During the same period last year, the firm earned $1.84 earnings per share. West Pharmaceutical Services has set its Q3 2026 guidance at 2.140-2.240 EPS and its FY 2026 guidance at 8.850-9.050 EPS.

West Pharmaceutical Services Dividend Announcement

The firm also recently declared a quarterly dividend, which will be paid on Wednesday, August 5th. Investors of record on Wednesday, July 29th will be given a $0.22 dividend. The ex-dividend date of this dividend is Wednesday, July 29th. This represents a $0.88 annualized dividend and a yield of 0.2%. West Pharmaceutical Services’s dividend payout ratio (DPR) is presently 11.76%.

Key Stories Impacting West Pharmaceutical Services

Here are the key news stories impacting West Pharmaceutical Services this week:

• Positive Sentiment: West Pharmaceutical posted Q2 2026 EPS of $2.37, ahead of the $2.08 consensus, while revenue of $872.3 million also topped estimates. The beat suggests strong operating momentum and is a key reason investors are bidding up the stock. West Pharmaceutical Services (NYSE:WST) Beats Expectations in Strong Q2 CY2026, Stock Soars
• Positive Sentiment: The company raised its 2026 outlook, guiding EPS to $8.85-$9.05 versus the prior/consensus view around $8.61, and revenue to about $3.3 billion-$3.4 billion. Higher guidance often supports the stock because it signals confidence in continued demand and earnings growth. West Pharmaceutical raises annual profit forecast on strong demand for injectable drug components
• Positive Sentiment: Management also lifted Q3 2026 guidance, forecasting EPS of $2.14-$2.24 and revenue of $820 million-$835 million, both modestly above expectations. This reinforces the view that the earnings beat was not a one-quarter event.
• Positive Sentiment: Reuters noted demand remains strong for injectable-drug components tied to diabetes and obesity treatments, a favorable end-market trend that could continue to support West’s growth.

Wall Street Analysts Forecast Growth

WST has been the subject of a number of recent research reports. BNP Paribas Exane began coverage on West Pharmaceutical Services in a report on Monday, July 13th. They set an “outperform” rating and a $447.00 price objective for the company. Wolfe Research started coverage on West Pharmaceutical Services in a research report on Monday, June 1st. They set an “outperform” rating and a $375.00 target price on the stock. KeyCorp upped their price target on West Pharmaceutical Services from $350.00 to $390.00 and gave the stock an “overweight” rating in a report on Thursday, July 2nd. Zacks Research upgraded West Pharmaceutical Services from a “hold” rating to a “strong-buy” rating in a report on Wednesday, May 13th. Finally, TD Cowen reissued a “buy” rating on shares of West Pharmaceutical Services in a research report on Wednesday, July 15th. Two investment analysts have rated the stock with a Strong Buy rating, eleven have assigned a Buy rating and two have given a Hold rating to the stock. Based on data from MarketBeat, the company presently has an average rating of “Buy” and an average price target of $363.17.

Insider Activity at West Pharmaceutical Services

In related news, VP Annette F. Favorite sold 2,817 shares of West Pharmaceutical Services stock in a transaction on Monday, April 27th. The stock was sold at an average price of $305.20, for a total transaction of $859,748.40. Following the sale, the vice president directly owned 16,828 shares in the company, valued at approximately $5,135,905.60. This trade represents a 14.34% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, CAO Chad Winters sold 896 shares of the business’s stock in a transaction on Monday, April 27th. The stock was sold at an average price of $300.67, for a total value of $269,400.32. Following the completion of the transaction, the chief accounting officer directly owned 1,523 shares in the company, valued at approximately $457,920.41. This represents a 37.04% decrease in their position. The disclosure for this sale is available in the SEC filing. Corporate insiders own 0.60% of the company’s stock.

Institutional Investors Weigh In On West Pharmaceutical Services

Hedge funds have recently made changes to their positions in the business. Nordea Investment Management AB lifted its holdings in West Pharmaceutical Services by 42.7% during the 4th quarter. Nordea Investment Management AB now owns 14,950 shares of the medical instruments supplier’s stock worth $4,122,000 after purchasing an additional 4,477 shares in the last quarter. Birch Hill Investment Advisors LLC grew its holdings in West Pharmaceutical Services by 11.5% during the 4th quarter. Birch Hill Investment Advisors LLC now owns 152,148 shares of the medical instruments supplier’s stock valued at $41,862,000 after buying an additional 15,678 shares in the last quarter. Brendel Financial Advisors LLC purchased a new position in West Pharmaceutical Services during the 4th quarter valued at about $3,742,000. DAVENPORT & Co LLC increased its position in shares of West Pharmaceutical Services by 559.8% during the fourth quarter. DAVENPORT & Co LLC now owns 9,521 shares of the medical instruments supplier’s stock valued at $2,620,000 after buying an additional 8,078 shares during the period. Finally, Annex Advisory Services LLC lifted its holdings in shares of West Pharmaceutical Services by 8.7% in the fourth quarter. Annex Advisory Services LLC now owns 122,958 shares of the medical instruments supplier’s stock worth $33,831,000 after buying an additional 9,800 shares in the last quarter. 93.90% of the stock is currently owned by institutional investors.

West Pharmaceutical Services Stock Performance

The business’s fifty day moving average price is $335.41 and its 200-day moving average price is $286.58. The company has a debt-to-equity ratio of 0.07, a current ratio of 2.71 and a quick ratio of 2.04. The stock has a market capitalization of $25.34 billion, a PE ratio of 47.96, a P/E/G ratio of 2.91 and a beta of 1.16.

About West Pharmaceutical Services

West Pharmaceutical Services, Inc is a global developer and manufacturer of components, systems and services that enable the containment and delivery of injectable drugs. The company focuses on high-quality packaging and delivery solutions for the pharmaceutical and biotech industries, producing primary drug packaging components and specialized drug delivery devices used for vaccines, biologics and other injectable therapies. West is known for its elastomeric closures, seals and polymer components that maintain sterility and compatibility with sensitive drug formulations.

In addition to component manufacturing, West provides engineered delivery systems and support services across the product lifecycle.